Hematologic Malignancy Clinical Trials in New York, New York

5 studies are recruiting for hematologic malignancy in New York, New York right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia

   The safety, tolerability, and antileukemic response of ziftomenib in combination with standard of care treatments for patients with relapsed/refractory acute myeloid leukemia will be examined with the following agents: FLAG-IDA, low-dose cytarabine, and gilteritinib.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Memorial Sloan Kettering Cancer Center, New York, New York

   Locations

   45 in total

   Run by

   Kura Oncology, Inc.

   See if you can join NCT06001788 on ClinicalTrials.gov

2. A Study of Belumosudil in People at Risk of Developing Graft-Versus-Host Disease After a Stem Cell Transplant

   The purpose of this study is to find out whether adding belumosudil to a usual approach for reducing the risk of graft-versus-host disease (GVHD) may be an effective GVHD prevention approach for people with blood cancer who have a stem cell transplant. The investigators will also look at the safety…

   Stage

   Phase 2

   Ages

   18 and older

   Site

   New York University (Data Collection Only), New York, New York

   Locations

   8 in total

   Run by

   Memorial Sloan Kettering Cancer Center

   See if you can join NCT07006506 on ClinicalTrials.gov

3. An Extension Study for Patients Previously Enrolled in Studies With Pelabresib

   The purpose of this study is to evaluate the long-term safety and the clinical benefit of pelabresib in patients with hematological and/or solid tumor indications or advanced malignancies. Additionally, participants previously enrolled in studies with pelabresib who received placebo or participants…

   Stage

   Phase 3

   Ages

   18 and older

   Site

   New York Presbyterian Hospital, New York, New York

   Locations

   15 in total

   Run by

   Novartis Pharmaceuticals

   See if you can join NCT06401356 on ClinicalTrials.gov

4. Prevention of GvHD in Participants With Hematological Malignancies Undergoing Hematopoietic Stem Cell Transplant (HSCT)

   The purpose of this Phase 1, first in human open-label study is to assess the safety and tolerability of TRX-103 in patients with hematological malignancies undergoing HLA-mismatched related or unrelated hematopoietic stem cell transplantation (HSCT). It is anticipated that up to 36 Subjects will b…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Memorial Sloan Kettering Cancer Center, New York, New York

   Locations

   5 in total

   Run by

   Tr1X, Inc.

   See if you can join NCT06462365 on ClinicalTrials.gov

5. Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies

   Tagraxofusp is a protein-drug conjugate consisting of a diphtheria toxin redirected to target CD123 has been approved for treatment in pediatric and adult patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN). This trial aims to examine the safety of this novel agent in pediatric patie…

   Stage

   Phase 1

   Ages

   1 to 21

   Site

   Memorial Sloan Kettering Cancer Center, New York, New York

   Locations

   31 in total

   Run by

   Therapeutic Advances in Childhood Leukemia Consortium

   See if you can join NCT05476770 on ClinicalTrials.gov